Abstract: Monoclonal antibodies having conformation-dependent specificity for native dsDNA, as exemplified by the IgM antibody produced by murine hybridoma ATCC No HB 8329. These antibodies are used to detect DNA duplex formation in DNA hybridization tests.

Abstract: Human peptide hormones, such as insulin, growth hormone, prolactin, adrenocorticotropic hormone, placental lactogen, calcitonin, parathyroid hormone and thyroid stimulating hormone, are produced by implanting a human.times.human hybridoma lymphoblastoid cell line capable of producing the human peptide hormone in a non-human warm-blooded animal. After a period of time, the resultant tumor is extracted and disaggregated and then cultured in vitro under conditions appropriate to accumulate the human peptide hormone. The human.times.human hybridoma lymphoblastoid cell line is preferably formed by fusing parent human cells inherently capable of producing the human peptide hormone with a human lymphoblastoid line, preferably of leukemic origin. This process permits a substantial increase in the amount of human peptide hormone which can be produced.

Abstract: The present invention relates to a process for the production of human epidermal growth factor (hEGF). More precisely, the present invention relates to a process for the mass production of hEGF, comprising in vivo or in vitro multiplication of human cells capable of producing hEGF, and in vitro cultivation of the multiplied human cells to produce hEGF. The hEGF production according to the present invention is much higher than that attained by conventional processes; thus, hEGF can be obtained in a sufficient amount for use in the prevention and treatment of human diseases.

Abstract: The present invention relates to a process for the production of human Multiplication-Stimulating Activity (hMSA).More precisely, the invention relates to a process for the mass production of low-cost hMSA, comprising in vivo multiplication of human cells capable of producing said substance, and subsequent in vitro production of hMSA with the multiplied human cells.hMSA production according to the present invention is much higher, about 2-50-fold higher in terms of hMSA production per cell, than that attained by conventional processes: thus, hMSA can be used in a sufficient amount in the prevention and treatment of human diseases.

Abstract: A process for the mass production of hCSF, comprises cell fusion of human lymphoblastoid cells with any human cells capable of producing said substance, in vivo multiplication of the resultant hybridoma cells, using a non-human warm-blooded animal, and in vivo cultivation of the multiplied hybridoma cells to produce hCSF. The hCSF production according to the present process is much higher than that attained by conventional processes; thus, hCSF can be used in a sufficient amount in the prevention and treatment of human diseases.

Abstract: Novel hybridomas, human monoclonal antibodies, and their uses are provided. Specifically CLNH5 is a human-human hybridoma which secretes IgM monoclonal antibodies specific for cervical of carcinomas. The monoclonal antibodies can find use in therapy and diagnosis, both in vitro and in vivo.The hybridoma CLNH5 was deposited at the A.T.C.C. for patent purposes as defined in M.P.E.P. 608.01(p) on Jan. 28, 1983 and given A.T.C.C. Accession No. HB8206.

Abstract: HBcAb in a biological fluid is adsorbed on a surface which is then coated with BSA. The coated surface is then incubated first in the sample and then in the presence of radiolabelled HBcAb.

Abstract: Synthetic seeds are produced by encapsulating asexual plant embryos with a nontoxic, biocompatible, water-soluble coating material. The encapsulation is effected by mixing asexual embryos with a synthetic coating material, dispensing such mixture as droplets onto a sterile surface, and drying such droplets to constant weight at room temperature to form detachable wafers consisting of one or more asexual embryos embedded in the synthetic coating material.

Abstract: Hybrid cell line for production of monocloral antibody to an antigen found on essentially all normal human T cells and on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.

Abstract: A monoclonal antibody produced by a hybridoma formed by the fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with thrombospondin. The monoclonal antibody reacts with human, bovine, and canine thrombospondin but not with the thrombospondin present in rabbit serum. The monoclonal antibody is capable of being used to identify human, bovine, and canine thrombospondin in ELISAs and by means of immunohistological techniques and also can be used to isolate such thrombospondin by when employed in immunoisolation techniques.

Abstract: A fast growing, continuous, functional rat thyroid cell strain, FRTL-5, which maintains functional characteristics of iodide uptake and thyroglobulin synthesis over prolonged periods of culture is cloned from FRTL cells obtained from primary cultures of Fischer rat thyroid glands. The FRTL-5 cells are cultured in a medium containing approximately 5 percent calf serum supplemented with a mixture of hormones, at least one of which is thyrotropin.The FRTL-5 cells are employed in a series of assays which measure thyroid stimulatory or inhibitory factors. The FRTL-5 system of assay specifically measures thymidine incorporation, cAMP elevation and iodide uptake and permits the evaluation of patient sera, particularly those afflicted with Graves' disease and other autoimmune thyroid diseases, thereby providing a means for determining appropriate methods of treatment.

Abstract: The present invention provides a stable, continuous human myeloma cell line which is capable of hybridization with antibody-producing cells of humans and other animals, the cell line being a mutant of GM 1500 human B cells and being deficient in hypoxanthine phosphoribosyltransferase. The invention also comprises processes for the production of hybrid cells employing the stable, HPRT-deficient human myeloma cell line, and processes for the production of antibodies employing such hybrid cells.

Abstract: A fast growing, continuous, functional rat thyroid cell strain, FRTL-5, which maintains functional characteristics of iodide uptake and thyroglobulin synthesis over prolonged periods of culture is cloned from FRTL cells obtained from primary cultures of Fischer rat thyroid glands. The FRTL-5 cells are cultured in a medium containing approximately 5 percent calf serum supplemented with a mixture of hormones, at least one of which is thyrotropin.The FRTL-5 cells are employed in a series of assays which measure thyroid stimulatory or inhibitory factors. The FRTL-5 system of assay specifically measures thymidine incorporation, cAMP elevation and iodide uptake and permits the evaluation of patient sera, particularly those afflicted with Graves' disease and other autoimmune thyroid diseases, thereby providing a means for determining appropriate methods of treatment.

Abstract: A method of determining the concentration of an antigen in a sample solution comprising(a) coating an antigen-protein conjugate onto a solid matrix,(b) conjugating an enzyme to an antibody specific for said antigen,(c) to a known quantity of a solution containing the antibody-enzyme conjugate of (b) adding a specified quantity of a sample containing an unknown amount of the antigen whose content is to be determined,(d) contacting the coated solid matrix of (a) with the solution (c) and incubate so as to effect binding between the antibody and antigen, some of the antigen being that from the sample and some being that on the solid matrix,(e) removing the solid matrix from the solution and washing,(f) immersing the solid matrix in a solution containing a known amount of an enzyme-substrate which is acted upon by the enzyme so as to effect reaction between the enzyme and enzyme-substrate to produce a product, and then separating the solid matrix form the solution of enzyme-substrate, and(g) then measuring the so

Abstract: A method for cultivating myocytes in suspension using water soluble chitosan is taught. The method results in the three-dimensional growth of the cultured myocytes as well as the inhibition of certain undesired cells.

Abstract: A sterile, stable lyophilized formulation of selectively oxidized microbially produced recombinant IL-2 in which the recombinant IL-2 is admixed with a water soluble carrier such as mannitol that provides bulk, and a sufficient amount of sodium dodecyl sulfate to ensure the solubility of the recombinant IL-2 in water. The formulation is suitable for reconstitution in aqueous injections for parenteral administration and it is stable and well tolerated in human patients. FIG. 1 illustrates a preferred method of purifying recombinant IL-2 suitable for use in preparing the formulations of the present invention.

Abstract: A heterologous expression product in host cells is separated from the host cell material by suspending the material in a buffered solution, disrupting the cells and separating the product as refractile material. The refractile material can be dissolved in a strongly denaturing solution, which is then weakened while keeping the protein in solution, thereby allowing unfolding and refolding of the protein.

Abstract: A method of distinguishing multiple subpopulations of a cell sample whereby resting and activated human natural killer cells subpopulations can be monitored. This method utilizes two monoclonal antibodies identified as anti-Leu 11 and anti-DR (or anti-Leu 10 or anti-transferrin receptor).

Abstract: A method of preparing simultaneously monoclonal antibodies specific for different cell-free products of activated human T lymphocytes is disclosed. Human T cells are activated in a medium supplemented with mouse serum rather than conventional calf serum. A supernatant prepared from the activated T cells is used to immunize mice. The dominant immunogens in the supernatant are the cell-free products of human T lymphocytes. The yield of hybrid cells which produce products reactive with cell-free products of human T lymphocytes is enhanced by injecting the immunized mice with a supernatant from mitogen-activated murine splenocytes. In addition, a novel radioimmunoadsorbent assay for screening hybrids to detect production of monoclonal antibodies reactive with cell-free products of human T lymphocytes is disclosed.

Abstract: A continuous hybridoma cell line which secretes recoverable quantities of monoclonal antibodies having specificity against Vitamin B.sub.6, which antibodies are useful in a method for detecting the presence of vitamin B.sub.6 in an animal sample.

Abstract: A treatment and prophylaxis of viral infections in mammals is provided. The method involves administering an amount of a contact-blocking viral inhibitor (CVI) sufficient to elevate the concentration of the viral inhibitor in the mammal's tissue above the naturally occurring concentration in that same tissue. Methods for purifying and concentrating CVI are presented. The cellular viral inhibitor is characterized by broad antiviral activity, potency, reversible inhibition of viral attachment, cross species activity and molecular size. Natural levels of CVI range from 6 U/0.1 ml in tears to 400 U/0.1 ml in gastric secretions, with titers between these ranges found in colostrum, milk, plasma, saliva and urine. Biochemical characterization of the CVI indicates that it resists denaturation by heat, acid and alkali, and it exhibits a molecular size on the order of 2500 daltons.

Abstract: Method and test kit for detecting Clq-containing complexes in human serum containing native serum Cl. The method uses a monoclonal antibody which selectively reacts with human Clq in the presence of native human serum Cl. Preparation of hybridomas generating such antibodies is also disclosed. The method is applicable to detection of autoimmune diseases and AIDS.

Abstract: Human lymphoblastoid cell line capable of acting as a fusion partner in the preparation of hybridomas is grown and selected under conditions whereby a cell line is obtained having greatly enhanced fusion efficiency over the parent cell line. The cell line is derived from UC 729 by growing in Iscove's modified serum-free medium with plating at relatively high densities, followed by cloning at limiting dilutions and selecting for high frequency fusion.The subject cell line referred to as WI-L2-729 HF.sub.2 has the A.T.C.C. designation number CRL 8062, having been deposited on Apr. 2, 1981.

Abstract: The present invention concerns an autologous precipitating antibody and the gp70 pigment-associated antigen on melanoma cells which it recognizes. The antibody is useful in detecting pigmented melanoma cells in excised specimen, serum or urine.

Abstract: A process for producing an adult T cell leukemia associated antigen is disclosed wherein an adult T cell leukemia associated antigen producing cell is treated with a surfactant. A method for assaying adult T cell leukemia associated antibodies by enzymoimmunoassay, radioimmunoassay or passive hemagglutination is also disclosed. In this method, the adult T cell leukemia associated antigen obtained by treating the adult T cell leukemia associated antigen producing cells with a surfactant is used as the antigen in the assay procedure.

Abstract: A panel of monoclonal antibodies produced from human gastrointestinal tumors as immunogen is used to diagnose the presence of colon cancer. The antibody panel subsets the human gastrointestinal tract in its reactivity vis-a-vis esophagus, stomach, small intestine and colon. The panel is useful as a diagnostic probe for cancer.

Abstract: Interleukin-2 receptor derived from normal and malignant cells has been purified by use of various techniques including affinity chromotography in conjunction with a monoclonal antibody directed to the receptor. Purification also involved reversed phased high performance liquid chromotography. By these techniques, interleukin-2 receptor has been purified to homogeneity. The high purification of the interleukin-2 receptor has enabled this protein molecule to be partially sequenced.

Abstract: Methods are provided for producing fusion partners which involve employing an immortalized human myeloma cell line sensitive to HAT and having an additional dominant selectable resistance marker and fusing the doubly marked human myeloma cells with a stable immortalized rodent myeloma cell line, desirably previously subjected to substantial chromosome damage, and isolating cells having a substantially complete chromosomal complement of the rodent cell and at least about one chromosome of the human cell having a gene expressing said resistance, thereby being resistant to a selective agent. The resulting heteromyeloma may be fused with high efficiency with human lymphocytes to produce monoclonal antibodies.The cell lines designated as A6 and 36 were deposited at the A.T.C.C. on Jan. 11, 1983 and given accession numbers CRL8192 and CRL8193, respectively.

Abstract: A method for producing monoclonal antibody reagents against novel proteins induced by herpes simplex virus type 1 (HSV-1). The method consists of preparing HSV-1 antigen populations by infecting mammalian cells either with HSV-1 alone or with HSV-1 in the presence of an inhibitor of protein synthesis, allowing virus replication to proceed by reversing the action of said inhibitor, inoculating said antigen mixture in mice to induce the production of antibodies, fusing the spleen cells of said mice with myeloma cells to obtain hybrid cells, and screening said cells by radioimmunoprecipitation-polyacrylamide gel electrophoresis (RIP-PAGE) to identify hybrid cells producing monoclonal antibodies against HSV-1 proteins. The method teaches the production of unique monoclonal antibody reagents directed against novel HSV-1 proteins; including a 132,000 molecular weight (mw) DNA-binding protein, a 175,000 mw immediate-early protein, and a previously unknown 110,000 mw glycoprotein.

Abstract: A continuous hybrid cell line which produces monoclonal antibody directed against the neurotransmitter degrading enzyme, monoamine oxidase B (MAO B), has been developed. The hybrid cell line was established by fusing MAO B primed, differentiated lymphoid cells with myeloma cells. Resulting fused cells were isolated, cloned and characterized as to antibody specificity against antigenic determinants of MAO B. Monoclonal antibody having specificity for MAO B and no cross reactivity with MAO A was selected and implemented in a radioimmunoassay technique for the selective measurement of MAO B concentration independent of its catalytic activity.

Abstract: This invention relates to processes which are used to produce, isolate, and characterize human rotavirus/animal rotavirus reassortants and to produce live attenuated vaccines and vaccine precursors. In the present strategy there is involved the new use of either (1) high titer hyperimmune antisera or (2) monoclonal antisera to select reassortants with the desired human phenotype. A point of novelty is the finding that antiserum or monoclonal antisera alone, so long as it possesses high titer neutralizing activity against only the 34-38Kd glycoprotein or of the animal parent, is sufficient to use for selection of reassortant rotaviruses with human phenotype. Also, the novel products are live attenuated vaccine precursors and vaccines.

Abstract: A composition is tested to determine whether it is a tumor promoter or a complete carcinogen by exposing a stable epithelial cell line to the composition for an incubation time period sufficient to induce morphological changes in the cell line. After the incubation time, the cells are observed by morphology changes induced by the composition, which changes are compared to that caused by a known tumor promoter or a known complete carcinogen.

Abstract: Monoclonal antibodies 703D4 and 704A1 detect human non-small cell lung cancer (non-SCLC) and distinguish non-SCLC from all other types of lung cancer and normal tissue cells. These two antibodies may be utilized in kit form to distinguish non-SCLC from other forms of lung cancer. These monoclonal antibodies bind to S.sup.35 methionine-incorporating protein doublets under reduced and unreduced conditions. The determinants bound by these antibodies on the 31 kiladalton protein are independent of each other as determined in radiolabelled competition assays.

Abstract: A method of growing anchorage-dependent cells is disclosed in which a substrate comprising a hydrogel is employed. The hydrogel is formed from an aqueous solution gelled with a crosslinked polymer of a hydrophilic monomer and includes a macromolecule capable of supporting cell growth.

Abstract: Anti-Sm antibodies are produced by the hybridoma technique and employed to test for lupus erythematosus in humans.

Abstract: A method and test kit are disclosed for detecting the presence of hepatitis B virus in a test specimen containing at least a portion of the DNA of the virus. A test reagent comprises cloned hepatitis B virus-DNA that has been repurified by treatment with a restriction enzyme and labelled to high specific activity with a radioactive label. The sample to be tested is fixed to a solid matrix, incubated in the presence of the test reagent under hybridization conditions and detected by hybridization to the labelled DNA probe. The uncombined HBV-DNA (labelled) is removed from the substrate, and the hybridized HBV-DNA determined by scintillation counting or by autoradiography of the substrate.

Abstract: Monoclonal antibodies specific for a protein associated with a lung surfactant complex, decreased levels of which are related to respiratory distress syndrome, are disclosed. The antibodies are useful for prediction and diagnosis of respiratory problems in newborns.

Abstract: The present invention concerns novel immunoprecipitating autologous antibodies which recognize the Class 1 gp90 antigen on melanoma cells. These antibodies, optionally tagged with a chromophoric or radioactive label and immobilized on an inert support, may be used to recognize and isolate the gp90 antigen from melanoma cell extracts. Monoclonal antibodies to melanoma may be screened with the gp90 antigen for those which recognize epitopes other than the FD antigenic system.The cell line containing the gp90 antigen which has been cultured in vitro is a source of gp90 antigen for generation of monoclonal antibodies which will be useful in analyzing the gp90 antigen for those epitopes which may be of diagnostic value in immunoassay of melanoma.

Abstract: An immobilized antibody system can be made by reacting an aminated core support with an antibody in the presence of a condensing agent which promotes the formation of the amide linkage. The immobilized antibody system is highly resistant to leaching, may be made incompressible, sterilizable, and pyrogen-free. Such an immobilized antibody system is well suited for repeated use with minimal change in its physical and biochemical properties.

Abstract: A substratum for cell culture which comprises a chemically modified collagen rich in either positive or negative charges when under culture conditions. The substratum is prepared by modifying the amino groups or carboxyl groups of collagen. The chemically modified collagen enhances the adherence and proliferation of animal cells much more actively than unmodified collagen in the presence or absence of bovine fetus serum. The cultured animal cells can be detached efficiently from the chemically modified collagen. This allows for highly selective isolation and recovery of the cultured animal cells which can be accomplished without incurring any injury from the chemically modified collagen.

Abstract: Hybridoma tumor cell line (ATCC Number CRL 8164). A monoclonal anti-erythropoietin antibody substance, Epoclonalan, produced by said cell line. Use of Epoclonalan in immonological methods for isolation of natural erythropoietin and for quantitative detection of erythropoietin in fluid samples.

Abstract: Disclosed is a new mouse-mouse hybridoma tumor cell line A.T.C.C. No. HB8209. A monoclonal antibody produced by said cell line is specifically immunologically reactive with erythropoietin and with a polypeptide whose amino acid sequence is substantially duplicative of a sequence extant is erythropoietin. Disclosed also are procedures for isolation of erythropoietin by affinity purification and for quantitative detection of erythropoietin in fluid samples.

Abstract: In vitro culture of the venom gland cells of the ant Pseudomyremex triplarinus is effected by removing venom gland tissue from a larva or pupa of P. triplarinus subjecting the tissue to a protease to separate out the cells therein and culturing the resultant cells in an isotonic saline medium comprising carbohydrate, amino acids guanosine 3',5'-cyclic monophosphate and adenosine 3',5'-cyclic monophosphoric acid, at least part of the medium having been conditioned with Spodoptera frugiperda cells. Such in vitro culture provides a practicable route to volume production of the biologically active materials which are useful for treating the symptoms of rheumatoid arthritis and which the venom gland cells are known to produce.

Abstract: Artificial plant growth media suitable for suspension cell culture of sunflower plant cells are provided. Methods of using the media for growth of suspension cell culture of sunflower plant cells are provided. Methods for screening the oil content of sunflower seeds produced by sunflower plants utilizing the suspension cell growth characteristics of sunflower plant cells are provided.

Abstract: A method for the mass production of interferon, wherein cultured cells are brought into contact with at least one polyhydric alcohol, thereby achieving a remarkable increase in the production of interferon from the cultured cells.

Abstract: This invention provides a human parental T cell line which can fuse with normal human T cells, and hybrid cell lines which are prepared by fusion of the human parental T cells and the human T cells, and which are capable of producing lymphokines. This invention also provides methods of obtaining such human T cell lines, and a method of producing lymphokines from such hybrid cell lines.

Abstract: A hybridoma cell line is disclosed that secretes monoclonal antibodies which serve as a high titer, reproducible, biological reagent useful in biological/medical research for isolating and identifying phosphotyrosine-containing proteins. In addition, the antibodies have potential uses in diagnosis of a variety of diseases, including certain cancers. The antibodies, which have demonstrated affinity for a variety of molecules containing o-phosphotyrosine residues, were prepared using a synthetic analog, p-azobenzyl phosphonate (ABP) covalently linked to a carrier protein, as the antigen.

Abstract: The present invention relates to a process for the production of human urokinase. More precisely, the present invention relates to a process for the mass production of human urokinase, comprising in vivo multiplication of human cells capable of producing human urokinase, using the nutrient body fluid of a non-human warm-blooded animal, and exposure of the multiplied human cells to an urokinase inducer. The human urokinase present production according to the invention is much higher than that attained by conventional methods; thus, human urokinase can be used in sufficient amount in the prevention and treatment of human diseases.

Abstract: The present invention relates to a process for growing cell cultures of diploid cells. The process comprises the steps of(a) introducing cell culture medium into a container containing cell support prepared by applying to glass or polysaccharide base support a solution of thermosetting plastic material comprising the reaction product of an aldehyde with a polyvinyl alcohol and then subjecting said support thus-coated to the effect of heat under sufficient conditions to permit hardening of said thermosetting plastic material and the sterilization of the thus-coated support;(b) adding human or animal diploid cells to the culture medium of step (a) to form a cell-containing culture medium; and(c) maintaining the cell-containing culture medium of step (b) under cell growth conditions.